Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
about
Oxidative DNA Damage Mediated by Intranuclear MMP Activity Is Associated with Neuronal Apoptosis in Ischemic StrokeInsights into the complex formed by matrix metalloproteinase-2 and alloxan inhibitors: molecular dynamics simulations and free energy calculationsGPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary.Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, stimulate angiogenesis by regulating expression of urokinase type plasminogen activator and matrix metalloprotease 2.The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.Increased activity of cell surface peptidases in HeLa cells undergoing UV-induced apoptosis is not mediated by caspase 3.Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons.Alterations in the properties of neonatal thalamocortical synapses with time in in vitro slices.Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia.PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cellsPARP-1 cleavage fragments: signatures of cell-death proteases in neurodegenerationPARP inhibitors: polypharmacology versus selective inhibition.Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines.Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog.Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injuryEffect of the PARP-1 inhibitor PJ 34 on excitotoxic damage evoked by kainate on rat spinal cord organotypic slices.Parp-1genetic ablation inEla-mycmice unveils novel roles for Parp-1 in pancreatic cancer
P2860
Q26765807-56D825E5-0FD5-452D-8925-19157522C91EQ28477370-9C0B82B0-A684-4E25-9CE0-BDC9129BB83BQ35001269-52F74411-AB3F-4501-BEDE-047B87E68444Q35052831-E8E96B68-D12E-43AD-8A2B-F2479B14D9D1Q35255891-C9D6E7D2-58E4-4E1D-9B39-5072A644E011Q35865937-32CA2EF5-A8E1-4519-9A26-3E0C82444314Q35987121-4C0F418B-3E82-4CF4-8A7B-7362A01C77DAQ36274286-EBA70F7D-101D-4CC1-AD79-B8AD16316C6AQ36913813-1FB79329-6F6B-4B70-AEBB-3A0BF2649A33Q37108864-75FD45DD-8E4C-46B3-BEC4-9D7026124774Q37278883-B4A4F0E1-A9F5-465B-BEDA-7C74DD397095Q37822920-1B4AE623-181E-438A-9ADA-6D6D8A7945EDQ38100299-1A61C988-A7F5-46FE-B44F-EF44C9B5ED3EQ38134049-F440C654-1E12-49C4-A75B-4B0C790C6681Q38596368-A952BE93-9D44-4D7F-9A94-C031F97A8419Q39455969-1334C314-508E-42C2-86E4-61BF8BE9ADCFQ39686250-CED03C0B-9BB6-4CBB-8690-9B49E0973F43Q42692416-8AD8E6C1-6352-4614-B26E-970BD65F1107Q44983633-DA627B5B-0E12-4FA3-8874-3F02B7AB7782Q59281988-5241AE23-601D-42B1-8CF1-6929E7BBDD28
P2860
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
@en
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
@nl
type
label
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
@en
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
@nl
prefLabel
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
@en
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
@nl
P2860
P50
P1476
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
@en
P2093
Andrew Holt
Arulmozhi D Kandasamy
P2860
P304
P356
10.1016/J.BBRC.2009.07.080
P407
P577
2009-07-18T00:00:00Z